Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations
Language English Country Switzerland Media print-electronic
Document type Journal Article
Grant support
RVO 64165
Ministerstvo Zdravotnictví Ceské Republiky (CZ)
Progres Q28/LF1
Univerzita Karlova v Praze
UNCE 204065
Univerzita Karlova v Praze
SVV 260367
Univerzita Karlova v Praze
EF16_013/0001674
European Regional Development Fund
BBMRI_CZ LM2015089
European Regional Development Fund
CZ.2.16/3.1.00/24509
European Regional Development Fund
PubMed
31471882
DOI
10.1007/s12253-019-00739-5
PII: 10.1007/s12253-019-00739-5
Knihovny.cz E-resources
- Keywords
- Fumarate hydratase, Leiomyoma with bizarre nuclei, Leiomyosarcoma, Usual leiomyoma,
- MeSH
- Cell Nucleus pathology MeSH
- Adult MeSH
- Fumarate Hydratase genetics MeSH
- Leiomyoma genetics pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation MeSH
- Biomarkers, Tumor genetics MeSH
- Uterine Neoplasms genetics pathology MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Fumarate Hydratase MeSH
- Biomarkers, Tumor MeSH
Leiomyoma with bizarre nuclei (LBN) is an uncommon variant of uterine smooth muscle neoplasm. Involvement of fumarate hydratase (FH) has been suggested in the pathogenesis of a subset of LBN. The goal of our study is to assess the clinicopathological, morphological, immunohistochemical and molecular findings focusing on FH in LBNs (n = 108) and compare it with the findings in usual leiomyomas (UL; n = 50) and leiomyosarcomas (LMS; n = 42). Immunohistochemically, loss of FH expression was found in 67/108 of LBN, 1/50 of UL and in no LMS. Class 4/5 FH mutations were detected in 15/53 LBN with sufficient DNA quality for molecular analysis. Pathogenic variants of the FH gene were detected in neither UL nor LMS. Local recurrence after surgery was present in 18/92 of LBN patients, 7 of which were histologically verified and 2 of which were found to be LBN. Our results confirmed that LBN behave in a benign fashion, although they may relapse. FH gene mutations were a common finding only in LBN, but not in UL and LMS. Immunohistochemistry with an antibody against FH seems to have a good sensitivity (87%) and moderate specificity (58%) with regard to predicting FH gene mutations and could be used as a screening method in tumors with features suggestive of FH alterations to identify patients who are at risk for the FH aberrations.
References provided by Crossref.org
Uterine leiomyoma with RAD51B::NUDT3 fusion: a report of 2 cases
Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours